Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FYN | P06241 | 8/20 | 0.45 |
| ▸ | MAPK10 | P53779 | 2/20 | 0.44 |
| ▸ | JAK2 | O60674 | 1/20 | 0.44 |
| ▸ | JAK1 | P23458 | 1/20 | 0.44 |
| ▸ | TYK2 | P29597 | 1/20 | 0.44 |
| ▸ | JAK3 | P52333 | 1/20 | 0.44 |
| ▸ | MAP3K11 | Q16584 | 4/20 | 0.42 |
| ▸ | GAK | O14976 | 1/20 | 0.41 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.40 |
| ▸ | ACVR1 | Q04771 | 1/20 | 0.40 |
| ▸ | KIT | P10721 | 2/20 | 0.39 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.39 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.39 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.39 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9989302 | 0.83 | PDGFRB (0.54) | FYNJAK2JAK1TYK2JAK3 | |
| SCHEMBL12074840 | 0.81 | FYN (0.49) | FYNMAPK10MAP3K11GAKKIT | |
| SCHEMBL12074838 | 0.79 | MAPK10 (0.43) | MAPK10 | |
| SCHEMBL29213981 | 0.79 | MET (0.41) | MAPK10PDGFRBPDGFRA | |
| SCHEMBL12074839 | 0.78 | FYN (0.53) | FYNMAP3K11GAKTGFBR1ACVR1 | |
| SCHEMBL12074221 | 0.76 | PDGFRB (0.58) | GAKPDGFRBPDGFRA | |
| SCHEMBL14892069 | 0.73 | PDGFRB (0.48) | FYNJAK2JAK1TYK2JAK3 | |
| SCHEMBL14903996 | 0.73 | PDGFRB (0.44) | FYNGAKCHEK2PDGFRBPDGFRA | |
| SCHEMBL12074703 | 0.72 | BRD4 (0.44) | FYNMAP3K11GAKTGFBR1ACVR1 | |
| SCHEMBL9989152 | 0.71 | PDGFRB (0.44) | FYNGAKPDGFRBPDGFRA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9102617-B2 | Antimicrobial agents | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 2015-08-11 | — | — | US | disclosed |
| US-9102617-B2 | Antimicrobial agents | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 2015-08-11 | — | — | US | disclosed |
| US-20130109713-A1 | ANTIMICROBIAL AGENTS | UNIVERSITY OF MEDICINE AND DENTISTRY OF NEW JERSEY | 2013-05-02 | — | — | US | disclosed |
| US-20130109713-A1 | ANTIMICROBIAL AGENTS | UNIVERSITY OF MEDICINE AND DENTISTRY OF NEW JERSEY | 2013-05-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130109713-A1 | ANTIMICROBIAL AGENTS | RPS4X, RPS4Y1, MRPL21 | FYN 4551/4885MAPK10 1881/4885JAK2 958/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.